Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KIND T cells |
Synonyms | |
Therapy Description |
KIND T cells are HLA-A2+ CD8+ T-lymphocytes engineered to express a T-cell receptor (TCR) targeting the histone H3.3 K27M (K28M) mutation, which potentially induce killing of tumor cells expressing HLA-A2+ and H3.3K27M (PMID: 29203539). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KIND T cells | KIND T cells are HLA-A2+ CD8+ T-lymphocytes engineered to express a T-cell receptor (TCR) targeting the histone H3.3 K27M (K28M) mutation, which potentially induce killing of tumor cells expressing HLA-A2+ and H3.3K27M (PMID: 29203539). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05478837 | Phase I | Cyclophosphamide + Fludarabine KIND T cells | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (PNOC018) | Recruiting | USA | 0 |